Losses of cytokines and chemokines are common genetic features of human cancers: the somatic copy number alterations are correlated with patient prognoses and therapeutic resistance

References

• Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463:899–905. doi:10.1038/nature08822.
   PubMed Web of Science ®Google Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–724. doi:10.1038/nature07943.
   PubMed Web of Science ®Google Scholar
• Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, Lawrence MS, Zhsng CZ, Wala J, Mermel CH, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45:1134–1140. doi:10.1038/ng.2760.
   PubMed Web of Science ®Google Scholar
• Kim TM, Xi R, Luquette LJ, Park RW, Johnson MD, Park PJ. Functional genomic analysis of chromosomal aberrations in a compendium of 8000 cancer genomes. Genome Res. 2013;23:217–227. doi:10.1101/gr.140301.112.
   PubMed Web of Science ®Google Scholar
• Mbeunkui F, Johann DJ Jr. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol. 2009;63:571–582. doi:10.1007/s00280-008-0881-9.
   PubMed Web of Science ®Google Scholar
• Morrison WB. Inflammation and cancer: a comparative view. J Vet Intern Med. 2012;26:18–31. doi:10.1111/jvim.2012.26.issue-1.
   PubMed Web of Science ®Google Scholar
• Pein M, Oskarsson T. Microenvironment in metastasis: roadblocks and supportive niches. Am J Physiol Cell Physiol. 2015;309:C627–638. doi:10.1152/ajpcell.00145.2015.
   PubMed Web of Science ®Google Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19:1423–1437. doi:10.1038/nm.3394.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, Xu Y, Khuong A, Hoang CD, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–945. doi:10.1038/nm.3909.
   PubMed Web of Science ®Google Scholar
• Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–1454. doi:10.1093/jnci/djm135.
   PubMed Web of Science ®Google Scholar
• Restifo NP. A “big data” view of the tumor “immunome”. Immunity. 2013;39:631–632. doi:10.1016/j.immuni.2013.10.002.
   PubMed Web of Science ®Google Scholar
• Atretkhany KN, Drutskaya MS, Nedospasov SA, Grivennikov SI, Kuprash DV. Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther. 2016;168:98–112. doi:10.1016/j.pharmthera.2016.09.011.
   PubMed Web of Science ®Google Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14:e218–228. doi:10.1016/S1470-2045(12)70582-X.
   PubMed Web of Science ®Google Scholar
• Wong HS, Chang CM, Liu X, Huang WC, Chang WC. Characterization of cytokinome landscape for clinical responses in human cancers. Oncoimmunology. 2016;5:e1214789. doi:10.1080/2162402X.2016.1214789.
   PubMed Web of Science ®Google Scholar
• Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603–607. doi:10.1038/nature11003.
   PubMed Web of Science ®Google Scholar
• Cao Q, Zhou M, Wang X, Meyer CA, Zhang Y, Chen Z, Li C, Liu XS. CaSNP: a database for interrogating copy number alterations of cancer genome from SNP array data. Nucleic Acids Res. 2011;39:D968–974. doi:10.1093/nar/gkq997.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–690. doi:10.1016/j.cell.2014.09.050.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research, N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615. doi:10.1038/nature10166.
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782–795. doi:10.1016/j.immuni.2013.10.003.
   PubMed Web of Science ®Google Scholar
• Tirosh I, Izar B, Prakadan SM, Wadsworth MH 2nd, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189–196. doi:10.1126/science.aad0501.
   PubMed Web of Science ®Google Scholar
• Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 2009;69:6871–6878. doi:10.1158/0008-5472.CAN-08-4490.
   PubMed Web of Science ®Google Scholar
• Kang CW, Jang KW, Sohn J, Kim SM, Pyo KH, Kim H, Yun MR, Kang HN, Kim HR, Lim SM, et al. Antitumor activity and acquired resistance mechanism of dovitinib (TKI258) in RET-rearranged lung adenocarcinoma. Mol Cancer Ther. 2015;14:2238–2248. doi:10.1158/1535-7163.MCT-15-0350.
   PubMed Web of Science ®Google Scholar
• Angelova M, Charoentong P, Hackl H, Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik B, Galon J, et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015;16:64. doi:10.1186/s13059-015-0620-6.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17:174. doi:10.1186/s13059-016-1028-7.
   PubMed Web of Science ®Google Scholar
• Varn FS, Andrews EH, Mullins DW, Cheng C. Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. Nat Commun. 2016;7:10248. doi:10.1038/ncomms10248.
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, et al. The tumor microenvironment and immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med. 2016;8:327ra326. doi:10.1126/scitranslmed.aad6352.
   Web of Science ®Google Scholar
• Mlecnik B, Bindea G, Angell HK, Sasso MS, Obenauf AC, Fredriksen T, Lafontaine L, Bilocq AM, Kirilovsky A, Tosolini M, et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci Transl Med. 2014;6:228ra237. doi:10.1126/scitranslmed.3007240.
   Web of Science ®Google Scholar
• Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004;4:11–22. doi:10.1038/nrc1252.
   PubMed Web of Science ®Google Scholar
• Finn OJ. Cancer immunology. N Engl J Med. 2008;358:2704–2715. doi:10.1056/NEJMra072739.
   PubMed Web of Science ®Google Scholar
• Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131–144. doi:10.1038/nrc.2016.14.
   PubMed Web of Science ®Google Scholar
• Bertazza L, Mocellin S. The dual role of tumor necrosis factor (TNF) in cancer biology. Curr Med Chem. 2010;17:3337–3352. doi:10.2174/092986710793176339.
   PubMed Web of Science ®Google Scholar
• Snell LM, McGaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol. 2017;38:542–557. doi:10.1038/nbt.2938.
   PubMed Web of Science ®Google Scholar
• Di Franco S, Turdo A, Todaro M, Stassi G. Role of type I and II interferons in colorectal cancer and melanoma. Front Immunol. 2017;8:878. doi:10.3389/fimmu.2017.00878.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol. 2015;15:405–414. doi:10.1038/nri3845.
   PubMed Web of Science ®Google Scholar
• Roberts NJ, Zhou S, Diaz LA Jr., Holdhoff M. Systemic use of tumor necrosis factor alpha as an anticancer agent. Oncotarget. 2011;2:739–751. doi:10.18632/oncotarget.v2i10.
   PubMedGoogle Scholar
• Van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist. 2006;11:397–408. doi:10.1634/theoncologist.11-4-397.
   PubMed Web of Science ®Google Scholar
• Malek JA, Mery E, Mahmoud YA, Al-Azwani EK, Roger L, Huang R, Jouve E, Lis R, Thiery JP, Querleu D, et al. Copy number variation analysis of matched ovarian primary tumors and peritoneal metastasis. PLoS One. 2011;6:e28561. doi:10.1371/journal.pone.0028561.
   PubMed Web of Science ®Google Scholar
• Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654–2666. doi:10.1056/NEJMoa051424.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313:1960–1964. doi:10.1126/science.1129139.
   PubMed Web of Science ®Google Scholar
• Han A, Glanville J, Hansmann L, Davis MM. Linking T-cell receptor sequence to functional phenotype at the single-cell level. Nat Biotechnol. 2014;32:684–692. doi:10.1038/nbt.2938.
   PubMed Web of Science ®Google Scholar
• Liu X, Venkataraman G, Lin J, Kiyotani K, Smith S, Montoya M, Nakamura Y, Kline J. Highly clonal regulatory T-cell population in follicular lymphoma - inverse correlation with the diversity of CD8+ T cells. Oncoimmunology. 2015;4:e1002728. doi:10.1080/2162402X.2014.1002728.
   PubMed Web of Science ®Google Scholar
• Jang M, Yew PY, Hasegawa K, Ikeda Y, Fujiwara K, Fleming GF, Nakamura Y, Park JH. Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. Oncoimmunology. 2015;4:e1030561. doi:10.1080/2162402X.2015.1030561.
   PubMedGoogle Scholar
• Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E. Chemotherapeutic drugs and human tumor cells cytokine network. Int J Cancer. 2008;123:2031–2040. doi:10.1002/ijc.v123:9.
   PubMed Web of Science ®Google Scholar
• Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP. Cytokines in cancer drug resistance: cues to new therapeutic strategies. Biochim Biophys Acta. 2016;1865:255–265.
   PubMed Web of Science ®Google Scholar
• Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011;12:R41. doi:10.1186/gb-2011-12-4-r41.
   PubMed Web of Science ®Google Scholar
• Davis S, Meltzer PS. GEOquery: a bridge between the gene expression omnibus (GEO) and bioconductor. Bioinformatics. 2007;23:1846–1847. doi:10.1093/bioinformatics/btm254.
   PubMed Web of Science ®Google Scholar
• Consortium GT. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45:580–585. doi:10.1038/ng.2653.
   PubMed Web of Science ®Google Scholar
• Yan X, Hu Z, Feng Y, Hu X, Yuan J, Zhao SD, Zhang Y, Yang L, Shan W, He Q, et al. Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell. 2015;28:529–540. doi:10.1016/j.ccell.2015.09.006.
   PubMed Web of Science ®Google Scholar
• Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, Schinzel AC, Sandy P, Meylan E, Scholl C, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462:108–112. doi:10.1038/nature08460.
   PubMed Web of Science ®Google Scholar